Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Ovarian Cancer
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Ovarian Cancer
    TopAbstracts in Ovarian Cancer 07/01/2009 - (DGNews)
    Mutation of FOXL2 in Granulosa-Cell Tumors of the Ovary - (N Engl J Med)
    Delayed Symptom Progression, Better Tolerability Found With Pegylated Liposomal Doxorubicin Plus Carboplatin for Ovarian Cancer: Presented at ASCO - (DGDispatch)
    TopAbstracts in Ovarian Cancer 06/03/2009 - (DGNews)
    TopAbstracts in Ovarian Cancer 05/06/2009 - (DGNews)

    News archive

     Recent webcasts/CME - Ovarian Cancer
    • Current Therapeutic Options and Clinical Issues in Recurrent Ovarian Cancer: Where Do We Stand?
    • Looking Ahead: Emerging Options in Treatment of Ovarian Cancer
    • Ovarian Cancer: Designed for the Primary Care Physician
      Gynecologic and Colorectal Cancer: Risks and Benefits of Contraceptive Methods

      Webcasts/CME archive

       Recent cases - Ovarian Cancer
        Choroidal Eye Metastases from (Recurrent) Primary Peritoneal Carcinoma: Case Report and Review of the Literature
        A Case of Meigs Syndrome Mimicking Metastatic Breast Carcinoma
        Uterine Tumours Resembling Ovarian Sex Cord Tumours: A Case Report
        Delayed Malignant Melanoma Recurrence Simulating Primary Ovarian Cancer
        Ruptured Ovarian Cystic Teratoma in Pregnancy with Diffuse Peritoneal Reaction Mimicking Advanced Ovarian Malignancy: A Case Report

        Cases archive
          




        my personal edition > ovarian cancer > news
        divider

          E-Mail this DGDispatch to a colleague

        DGDispatch


        Intraperitoneal Carboplatin/Paclitaxel Safe With Good Pharmacokinetic Profile for Advanced Ovarian Cancer: Presented at ASCO

          By Cameron Johnston

          CHICAGO, IL -- June 4, 2007 -- Women with advanced ovarian cancers who are treated with an intraperitoneal regimen (IP) of carboplatin and paclitaxel fare better than patients in a previous study who were treated with IP cisplatin/paclitaxel.

          Both regimens also appear to have favourable results compared with the conventional intravenous administration of the drugs.

          In a poster discussion here on June 3rd at the 43rd American Society of Clinical Oncology Annual Meeting (ASCO), Carolyn N. Krasner, MD, medical oncologist, Massachusetts General Hospital, Boston, Massachusetts, United States, said the pharmacokinetics of the study showed positive results, with relatively few toxicities.

          Administration of chemotherapy by the IP route has been done in the past but it is a labour-intensive procedure, Dr. Krasner said. Her study was designed to evaluate the pharmacokinetics, efficacy, and toxicity of the dual-agent regimen. Past studies have shown that IP dosing results in a lower maximum concentration and a significantly higher area under the curve (AUC) compared with IV administration.

          Another aim of the study was to determine whether systemic uptake of the drugs changed over time, since there has been some suggestion that IP administration would cause the peritoneum to sclerose, which would then impair systemic absorption of future treatments.

          In the study, 40 women with advanced ovarian cancer (36 with stage III disease, all had been optimally debulked) received their first dose of carboplatin/paclitaxel as an IV infusion. The next 5 administrations were intraperitoneal. Carboplatin was delivered at AUC6 on day 1, and paclitaxel was given at a dose of 60 mg/m2 on days 1, 8, and 15. Patients who completed all 6 cycles underwent a second-look operation (SLO).

          Twenty-six women were able to complete all 6 cycles, which is better than what was seen in the prior study with cisplatin/paclitaxel, Dr. Krasner said.

          Toxicity was mild, he said, with grade 3 or 4 toxicity consisting of neutropenia in 10 patients (25%), vomiting in 2 patients (5%), fatigue in 2 patients (5%), and fatigue and anaemia in 2 patients (5%). There was no grade 3 or 4 peripheral neuropathy or alopecia.

          Twenty-four women underwent SLOs. A complete pathological response was seen in 17 (72%) patients, which Dr. Krasner said was an extremely good finding. This compares with 57% who showed a complete pathological response in the earlier cisplatin/paclitaxel trial.

          Five women were determined to be microscopically positive when the SLO was done.

          Dr. Krasner said problems with the port insertion, mainly infections, are still an issue that needs to be worked out, but the rate of port problems did not increase for women who were having weekly delivery of the paclitaxel as compared with those who had less frequent administrations.

          Overall, Dr. Krasner commented, the pharmacokinetic results of this study were encouraging and the tolerability and efficacy results suggest the study should be replicated in a larger population of women.


          [Presentation title: Results of All-Intraperitoneal Carboplatin and Paclitaxel Regimen Shows Good Tolerability and Efficacy for Advanced Ovarian Cancer. Abstract 5521]




        E-Mail this DGDispatch to a colleague   To print, use this version






        All contents Copyright (c) 1995-2009 Doctor's Guide Publishing Limited. All rights reserved.



        The NTK initiative. Physicians helping physicians identify Need-To-Know science
           Feedback
        Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
        Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
        1
        2
        3
        4
        5
        6
        7
        Send